Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors

What is it about?

As immunotherapies are becoming standard therapies in multiple types of tumor, increasing attention has been paid to immune-related adverse events (irAE), especially gastrointestinal AE, which can be serious or even fatal. Our review supports the use of the current management guidelines, and recommends that recurrent cases be treated carefully regardless of the grade of diarrhea at the onset of events.

Featured Image